Skip to main content
TipRanks
Go Ultimate75% OFF

Edwards Lifesciences (0REN) AI Stock Analysis

1 Followers
GB:0REN

Edwards Lifesciences

(LSE:0REN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Balance Sheet StrengthVery low leverage and steadily rising equity provide Edwards with financial flexibility to fund research, regulatory programs, and commercial expansion. This balance-sheet strength can help the company absorb operating volatility while preserving capacity to invest in structural-heart opportunities over the next several quarters.
Negative Factors
Operating Margin CompressionThe decline in operating profitability suggests that higher costs, investment intensity, or product mix are absorbing part of the benefit from revenue growth. Unless margins recover, earnings may compound more slowly than sales and the company will have less operating leverage during periods of demand or currency pressure.

Edwards Lifesciences Business Overview & Revenue Model

Company Description

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United...

Edwards Lifesciences Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|Next Earnings Date:Jan 27, 2027
Earnings Call SentimentPositive

The call was strongly positive. Edwards reported better-than-expected third-quarter results, raised full-year sales, TAVR, TMTT and EPS guidance, highlighted broad clinical and regulatory progress, and expressed confidence in durable long-term growth. The main challenges were GAAP EPS impairment, foreign-exchange and tax headwinds, expected fourth-quarter margin phasing, moderating TAVR share gains and the gradual timing of new-indication benefits.

Positive Updates

Strong Third-Quarter Company Performance
Third-quarter sales were $1.72 billion, growing 11.2% year-over-year and exceeding expectations, with broad-based performance across businesses and regions. Adjusted EPS was $0.80.

Negative Updates

GAAP EPS Impacted by Asset Impairment
Third-quarter GAAP EPS was $0.53, primarily driven by the impairment of a certain research and development asset, compared with adjusted EPS of $0.80.

Company Guidance

Management raised full-year 2026 total sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97 to $3.05, growing 18% at the midpoint versus prior year; fourth-quarter sales are projected at $1.67 billion to $1.75 billion with adjusted EPS of $0.61 to $0.69. Full-year TAVR guidance is 9% to 9.5%, with durable mid- to high single-digit growth over the long term; TMTT sales are expected to be between $780 million and $790 million, supporting a path to $2 billion in TMTT revenue in 2030; and Surgical guidance remains mid-single-digit sales growth. Adjusted gross margin is expected at the lower end of the full year 78% to 79% gross margin guidance, operating margin at the high end of the original 28% to 29% guidance with approximately 150 basis points of constant currency operating margin expansion, fourth-quarter operating margin in the mid-20s, R&D expense at approximately 16.5% of sales, effective tax rate at the high end of 16% to 19%, fourth-quarter FX headwind of approximately $15 million, and average diluted shares outstanding between 575 million and 580 million; beyond 2026, Edwards plans for 50 to 100 basis points of underlying operating margin expansion and approximately 10% average annual sales growth alongside leveraged EPS growth.

Edwards Lifesciences Risk Analysis

Edwards Lifesciences disclosed 28 risk factors in its most recent earnings report. Edwards Lifesciences reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Edwards Lifesciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0REN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.58B25.1510.60%2.78%9.77%12.28%
LIVNLIVN77Outperform$5.03B25.5115.35%―11.71%―
ABTABT67Neutral$187.95B40.199.11%2.32%10.00%-66.06%
PENPEN67Neutral$12.65B80.4310.44%―16.98%-5.62%
BSXBSX64Neutral$64.27B18.7113.87%―8.88%25.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%ABTBSXMDTPENLIVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0REN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ABTAbbott Laboratories108.52-18.36-14.47%
BSXBoston Scientific44.34-57.42-56.43%
MDTMedtronic102.869.6710.38%
PENPenumbra Inc.320.9142.4015.22%
LIVNLivaNova PLC91.3237.6870.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.